Bridge­Bio to raise $150M; FDA ac­cepts Ion­is' an­ti­sense drug NDA

Af­ter Bridge­Bio pub­licly dis­closed a Phase II win Mon­day morn­ing, it’s now want­i­ng $150 mil­lion.

The biotech said Mon­day af­ter­noon that it start­ed an un­der­writ­ten pub­lic of­fer­ing for $150 mil­lion worth of shares, al­low­ing un­der­writ­ers to buy an ad­di­tion­al $22.5 mil­lion in shares.

An SEC fil­ing from the biotech says the funds are in­tend­ed to push for­ward clin­i­cal and pre­clin­i­cal de­vel­op­ment — help­ing to pay for re­search ac­tiv­i­ties and work­ing cap­i­tal. The fil­ing al­so says Bridge­Bio “may al­so use a por­tion of the net pro­ceeds to in­vest in or ac­quire busi­ness­es or tech­nolo­gies that we be­lieve are com­ple­men­tary to our own.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA